DempoChem Logo
  1. HomeHome
  2. /ProductsProducts
  3. /Building BlocksBuilding Blocks
  4. /Heterocyclic ScaffoldsHeterocyclic Scaffolds
  5. /IndolesIndoles
  6. /SemaglutideSemaglutide
Chemical structure of CAS 910463-68-2

Semaglutide

In Stock•Starting at $41 for 5 mg•Purity ≥ 98%
CAS No.910463-68-2
MDL No.N/A
MFC187H291N45O59
MW4114.00
InChI KeyDLSWIYLPEUIQAV-CCUURXOWSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT→

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
5 mg99%$41In Stock
10 mg99%$60In Stock
25 mg99%$79In Stock
50 mg99%$135In Stock
100 mg99%$210In Stock
250 mg99%$304In Stock
1 g99%$493In Stock
5 g99%$1508In Stock
10 g98%$2424In Stock
25 g98%$4842In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Semaglutide is a 31-amino-acid polypeptide linked by peptide bonds, acting as a GLP-1 receptor agonist. It is used to treat type 2 diabetes and functions as a hypoglycemic agent, anti-obesity agent, neuroprotective agent, and appetite suppressant. It is also classified as a lipopeptide.

CAS No.910463-68-2
Product NameSemaglutide

Biological Targets

GLP1R

Associated Conditions

asthma·alcohol dependence·overweight body mass index status·Parkinson disease·diabetic nephropathy·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The multifaceted effects of semaglutide: exploring its broad therapeutic applications.

Future science OA • Vol. 11, Issue 1 • 2025
PMID: 40904035PMC: PMC12413075DOI: 10.1080/20565623.2025.2483607

Semaglutide attenuates lipotoxicity-induced cardiac injury by inhibiting Slc27a2 expression.

Chemico-biological interactions • Vol. 418 • 2025
PMID: 40456371DOI: 10.1016/j.cbi.2025.111583

One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction.

Med (New York, N.Y.) • Vol. 5, Issue 3 • 2024
PMID: 38460497DOI: 10.1016/j.medj.2023.12.012

Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF.

Current opinion in cardiology • Vol. 39, Issue 3 • 2024
PMID: 38294187DOI: 10.1097/HCO.0000000000001117

Documentation

Similar Products

  • Liraglutide

    CAS No.204656-20-2

  • Semaglutide intermediate P29

    CAS No.1169630-82-3

Your Partner for
Complex Chemistry
logo
  • About Us
  • Perspectives
  • Products
  • Contact
  • Preclinical Development
  • Technologies
  • Custom Synthesis
Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
logo

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

©2026 DempoChem. All Rights Reserved.
DHLFedExUPSPostNL
CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|
  • Products
    • CDMO Compounds
    • API & Candidates
  • Services
    CDMO & Manufacturing
    • Custom Synthesis
    • Process Development
    • Lab To Pilot
    • Commercialization
    • Generic APIs
    CRO
    • Preclinical
    • Pharmacology & Efficacy
    • DMPK & Bioanalysis
    • Toxicology & Safety
    • Disease Models
    Technologies
    • High-Potent
    • Chiral Synthesis
    • Cloud Synthesis
    • Fermentation
    • Flow Chemistry
    • Biocatalysis
    Support
    • Regulatory Support
    • Supply Chain Solutions
  • About
  • Perspectives
  • Contact